PRRG2 Antibody

What is PRRG2 and why is it significant in cellular research?

PRRG2 (Proline-Rich Gla (G-Carboxyglutamic Acid) Polypeptide 2) is a single-pass transmembrane protein containing an N-terminal gamma-carboxyglutamic acid (Gla) domain and tandem Pro/Leu-Pro-Xaa-Tyr (PY) motifs at its C-terminal end. This protein is significant because:

• It represents one of the four known transmembrane-carboxyglutamic acid proteins in vertebrates

• The Gla domain is exposed extracellularly, while PY motifs are cytoplasmic

• It interacts with YAP1 (Yes-associated protein), suggesting involvement in signal transduction pathways

• It undergoes γ-glutamyl carboxylation in a manner dependent on a proteolytically cleavable propeptide and sensitive to warfarin

• Recent research indicates significant roles in immune response regulation and potential implications in cancer biology

What are the key structural components of PRRG2 that researchers target with antibodies?

Researchers typically target these key structural regions of PRRG2:

• N-terminal Gla domain (amino acids ~1-45): Contains γ-carboxyglutamic acid residues; exposed on the cell surface

• Transmembrane segment: Single-pass membrane-spanning region

• C-terminal cytoplasmic region: Contains tandem PY motifs that interact with YAP1

• Full-length protein (179-202 amino acids depending on isoform)

Commonly available antibodies target these regions:

• AA 1-179 (full-length protein)

• AA 50-110 (partial protein)

• AA 71-120 (middle region)

The selection of appropriate epitope regions is critical for experimental success based on protein accessibility and experimental conditions .

How should researchers validate PRRG2 antibodies for experimental applications?

Proper validation of PRRG2 antibodies should include:

Step 1: Specificity Testing

• Western blot analysis using cell lines with known PRRG2 expression (e.g., HCT 116, A549, NCI-H1299)

• Comparison between control and PRRG2 overexpression lysates

• Testing in multiple species if cross-reactivity is claimed

Step 2: Application-Specific Validation

• For immunohistochemistry: Analyze staining patterns in tissues with known PRRG2 expression (e.g., kidney, thyroid gland)

• For immunofluorescence: Confirm subcellular localization patterns match published data (membrane localization)

Step 3: Correlation Testing

• Compare results with orthogonal methods (e.g., qRT-PCR)

• Verify knockdown/knockout specificity if possible

Step 4: Documentation

• Record antibody lot, concentration, experimental conditions

• Include appropriate positive and negative controls in all experiments

Examples of validation experiments from published research show that in western blot applications, PRRG2 should appear at approximately 22 kDa, while in IHC-P applications, membrane staining patterns should be observed in specific tissues like heart myocytes .

What are the critical differences between monoclonal and polyclonal PRRG2 antibodies for research applications?

For detecting PRRG2 in complex samples or for detecting post-translational modifications, the choice between monoclonal and polyclonal antibodies is critical. Monoclonal antibodies like clone 7D1 are ideal for highly specific detection of human PRRG2, while polyclonal antibodies may offer better detection in cross-species experiments and applications requiring higher sensitivity .

What are the optimal protocols for using PRRG2 antibodies in immunohistochemistry-paraffin (IHC-P) applications?

Recommended IHC-P Protocol for PRRG2 Detection:

Pretreatment:

• Heat-induced epitope retrieval (HIER) at pH 6.0 is strongly recommended

• Use citrate buffer and heat at 95-98°C for 20 minutes

Antibody Dilution:

• For polyclonal antibodies: 1:50 - 1:200 dilution range

• For monoclonal antibodies: Follow manufacturer's recommendations, typically 1:100 - 1:500

Detection System:

• HRP-conjugated secondary antibody with DAB substrate provides optimal visualization

• Counterstain with hematoxylin for nuclear contrast

Controls:

• Positive control: Thyroid gland or heart muscle tissue (shows strong membranous positivity in myocytes)

• Negative control: Omit primary antibody

Critical Considerations:

• Fixation time greatly impacts antibody performance; optimal fixation in 10% neutral buffered formalin for 24 hours

• Include both normal and disease tissue (e.g., KIRC samples) when evaluating PRRG2 expression patterns

• Quantification should include both staining intensity and percentage of positive cells

Research has shown that PRRG2 protein levels are significantly lower in KIRC tissues compared to normal kidney tissues, making proper protocol optimization essential for detecting these differences .

How can researchers optimize Western blot protocols for detecting PRRG2?

Optimized Western Blot Protocol for PRRG2:

Sample Preparation:

• For membrane proteins like PRRG2, use membrane extraction protocols with appropriate detergents

• A549 membrane extracts have been successfully used as positive controls

Gel Selection:

• 15% SDS-PAGE gels are recommended for optimal resolution of the 22 kDa PRRG2 protein

Transfer Conditions:

• PVDF membranes are preferred over nitrocellulose for transmembrane proteins

• Semi-dry transfer: 15V for 60 minutes

Blocking:

• 5% non-fat dry milk in TBST for 1 hour at room temperature

Primary Antibody:

• Dilution range: 0.04-0.4 μg/ml for most PRRG2 antibodies

• Incubate overnight at 4°C for optimal sensitivity

Detection Strategy:

• Enhanced chemiluminescence with exposure times starting at 30 seconds

• Expected band size: 22 kDa

Troubleshooting:

• Multiple bands may indicate different isoforms or post-translational modifications

• Larger bands (~26 kDa) may indicate propeptide-containing immature forms as PRRG2 undergoes propeptide cleavage for maturation

• No signal may require membrane extraction optimization or higher antibody concentration

Analysis of PRRG2 in multiple cell lines has shown variable expression levels, with significantly reduced mRNA levels in kidney carcinoma cell lines compared to HK-2 normal kidney cells .

How does PRRG2 expression correlate with clinical parameters in kidney renal clear cell carcinoma (KIRC)?

Research has established significant correlations between PRRG2 expression and clinical parameters in KIRC:

Expression Pattern:

• PRRG2 expression is markedly decreased in KIRC tissues compared to normal kidney tissues

• Both mRNA and protein levels show consistent downregulation

Correlation with Clinical Parameters:

Prognostic Significance:

These findings suggest that PRRG2 antibodies are valuable tools for investigating the role of PRRG2 in KIRC progression and for developing potential prognostic biomarkers for clinical applications.

What mechanisms might explain PRRG2's role in immune infiltration within tumor microenvironments?

PRRG2 appears to play a significant role in immune infiltration through several mechanisms:

Immune Response Regulation:

• Gene Ontology (GO) analysis reveals PRRG2 enrichment in immune response-related processes

• Specifically enriched in immune response-activating cell surface receptor signaling pathways

Correlation with Immune Cell Infiltration:

• PRRG2 expression shows significant associations with infiltration of:

  • B cells

  • CD8+ T cells

  • CD4+ T cells

  • Neutrophils

  • Macrophages

  • Dendritic cells

Signaling Pathway Involvement:

• GSEA enrichment analysis shows significant enrichment in immune-related activities:

  • Antigen activities B cell receptor (BCR) leading to secondary messenger generation

  • CD22-mediated BCR regulation

  • Immunoregulatory interactions between lymphoid and non-lymphoid cells

Proposed Mechanistic Model:

• PRRG2 influences immune cell recruitment and activation in the tumor microenvironment

• Lower PRRG2 expression may contribute to immune evasion by tumor cells

• The Gla domain, exposed extracellularly, may interact with immune cell receptors

• Intracellular signaling through PY motifs and YAP1 interaction may regulate expression of immune-related factors

Researchers investigating PRRG2 in immune contexts should consider these pathways when designing functional experiments using PRRG2 antibodies for in vitro and in vivo studies.

How can researchers address cross-reactivity concerns when using PRRG2 antibodies in multi-species studies?

Cross-reactivity is a critical consideration for PRRG2 antibody applications across species:

Sequence Homology Analysis:

• Human PRRG2 shares approximately 86% sequence identity with mouse and rat orthologs

• Regions with highest conservation are ideal targets for cross-reactive antibodies

Recommended Approaches:

• Pre-experimental Validation:

  • Perform sequence alignment between target species

  • Test antibodies on positive control tissues from each species

  • Validate with recombinant proteins if available

• Species-Specific Epitope Selection:

  • For species-specific detection, target divergent regions

  • For cross-species detection, target conserved epitopes

• Technical Controls for Cross-Reactivity:

  • Include samples from knockout/knockdown models

  • Use peptide competition assays to confirm specificity

  • Employ orthogonal detection methods (qRT-PCR, mass spectrometry)

• Commercial Antibody Selection:

  • Several antibodies have confirmed cross-reactivity with mouse and rat:

    • ABIN6744772 (reactivity: bat, cow, dog, human, mouse, rat)

    • NBP1-87229 (validated: human; predicted: mouse, rat)

When selecting antibodies for cross-species studies, researchers should prioritize products with experimental validation in the target species rather than relying solely on predicted cross-reactivity based on sequence homology.

What are the best approaches for studying post-translational modifications of PRRG2, particularly γ-carboxylation?

Studying γ-carboxylation of PRRG2 requires specialized approaches:

Experimental Design Considerations:

• Sample Preparation:

  • Use vitamin K-supplemented media for cell culture experiments

  • Warfarin treatment serves as a negative control by inhibiting γ-carboxylation

  • Consider membrane fractionation to enrich for mature, processed PRRG2

• Detection Methods:

  • Conformation-dependent antibodies: Select antibodies that specifically recognize carboxylated Gla domains

  • Mobility shift assays: γ-carboxylated vs. non-carboxylated forms have different electrophoretic mobility

  • Mass spectrometry: Most definitive for identifying modified residues

• Functional Validation:

  • Expression systems with enzymatically biotinylated proteins for purification and detection

  • Propeptide-cleaved (mature) vs. uncleaved forms can be distinguished by size

• Experimental Controls:

  • PRRG2 mutants lacking propeptide cleavage sites

  • Vitamin K-dependent carboxylase (GGCX) inhibition

  • Other vitamin K-dependent proteins as positive controls

Protocol for γ-Carboxylation Analysis:

• Express PRRG2 in cells with vitamin K supplementation (5 μg/ml)

• Parallel culture with warfarin (2 μM) as negative control

• Membrane extraction with appropriate detergents

• Western blot analysis to detect mobility shifts

• Confirmation by mass spectrometry for definitive site identification

Research has demonstrated that PRRG2 undergoes γ-glutamyl carboxylation in a manner dependent on a proteolytically cleavable propeptide, similar to other vitamin K-dependent proteins .